Dosing and uses of Carmol HC, U-Cort (urea/hydrocortisone topical)
Adult dosage forms and strengths
urea/hydrocortisone topicaL
topical cream
- 10%/1%
Dermatoses
Relief of inflammation and pruritic associated with corticosteroid-responsive dermatoses
Apply to affected area q6-12hr; discontinue therapy when control achieved
If no improvement within 2 weeks, reassess diagnosis
Pediatric dosage forms and strengths
Dosing Forms & Strengths
Urea/hydrocortisone topicaL
topical cream
- 10%/1%
Dermatoses
Apply to affected area q6-12hr; discontinue therapy when control achieved
If no improvement within 2 weeks, reassess diagnosis
Limit use in children to least amount compatible with an effective therapeutic regimen
Carmol HC, U-Cort (urea/hydrocortisone topical) adverse (side) effects
Frequency not defined
Burning
Itching
Irritation
Dryness
Folliculitis
Hypertrichosis
Acneiform eruptions
Hypopigmentation
Perioral dermatitis
Allergic contact dermatitis
Maceration of the skin
Secondary infection
Skin atrophy
Striae
Miliaria
Warnings
Contraindications
Hypersensitivity to any components of preparation
Hepatic insufficiency
Cautions
Prolonged use may result in fungal or bacterial infection
Contains sodium metabisulfite, which may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia and glucosuria
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use and the addition of occlusive dressings Evaluate susceptible patients periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests; If HPA axis suppression is noted, withdraw the drug, reduce frequency of application, or substitute less potent steroid
Pregnancy and lactation
Pregnancy category: C
Lactation: Systemic hydrocortisone is excreted in breast milk, use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Carmol HC, U-Cort (urea/hydrocortisone topical)
Mechanism of action
Hydrocortisone: anti-inflammatory, antipruritic and vasoconstrictive actions; mechanism of anti-inflammatory activity of topical corticosteroids unclear
Absorption
Extent determined by many factors including vehicle, integrity of epidermal barrier, use of occlusive dressings
Protein Bound
Variable
Metabolism
Primarily by liver
